What is the anticholinergic burden of nightly hydroxyzine 50 mg for sleep, and does it increase the risk of dementia in patients younger than 65?

Hydroxyzine 50mg Nightly: High Anticholinergic Burden with Dementia Risk

Hydroxyzine 50mg taken nightly for sleep carries a significant anticholinergic burden and should be avoided, even in patients under age 65, due to established associations with increased dementia risk and immediate cognitive impairment. 1

Anticholinergic Burden Classification

Hydroxyzine is classified as having strong anticholinergic properties with an Anticholinergic Cognitive Burden (ACB) score of 3 (definite anticholinergic activity) 2, 3. At 50mg nightly, this represents a substantial daily anticholinergic load that accumulates over time.

The drug exhibits broad muscarinic receptor blockade affecting:

• Vision (blurred vision, increased intraocular pressure risk)
• Urination (urinary retention, especially problematic with benign prostatic hypertrophy)
• Bowel function (constipation)
• Cognition (confusion, memory impairment, delirium risk)
• CNS effects (sedation, impaired driving performance, falls risk) 4, 5, 6

Dementia Risk: Not Limited to Elderly

The dementia risk from anticholinergic medications is NOT exclusive to those over 65. Recent high-quality evidence demonstrates:

• Cumulative exposure to strong anticholinergics shows a dose-dependent relationship with dementia risk 2. In a 2025 Swedish nationwide study of 199,526 dementia cases, even 1-89 total defined daily doses (DDDs) increased dementia risk (adjusted OR 1.10), with risk escalating to OR 1.66 for ≥1095 DDDs.

• The association was MORE pronounced in younger individuals and men 2, directly contradicting the assumption that only elderly patients face risk.

• Antihistamines specifically (hydroxyzine's drug class) showed significant associations with dementia when examining drug classes individually 2, 3.

• A 2018 UK study found increased dementia risk with anticholinergic exposure occurring 15-20 years before diagnosis 3, meaning middle-aged use (40s-50s) contributes to dementia risk in later life.

Clinical Implications for Sleep Management

For insomnia treatment, the evidence is clear:

1. There is insufficient evidence to recommend treating insomnia with medications as a dementia prevention strategy 1. The 2020 Canadian Consensus Conference (100% expert agreement) explicitly states: "Although associated with incident cognitive decline and dementia, there is insufficient evidence to recommend treatment of insomnia...with a goal of improving cognition and decreasing the risk of dementia."

2. First-generation antihistamines like hydroxyzine are NOT preferred for sleep 7. The 2009 JAGS guidelines concluded "there is no systematic evidence for the effectiveness of antihistamines...used off-label for the treatment of insomnia and warned that the risks of use outweighed the benefits."

3. Bedtime dosing does NOT eliminate next-day impairment 4. Hydroxyzine and its metabolites have prolonged half-lives, causing daytime drowsiness, decreased alertness, and performance impairment without subjective awareness.

4. The FDA label warns about CNS depression, QT prolongation risk, and specifically cautions about use in elderly 6, though as noted, younger patients are not exempt from cognitive risks.

Specific Recommendations

Immediate action:

• Discontinue hydroxyzine and substitute with evidence-based sleep interventions 1, 5, 8
• Target 7-8 hours of sleep through behavioral modifications rather than anticholinergic medications 1

Alternative approaches:

• Cognitive behavioral therapy for insomnia (CBT-I) - first-line treatment
• Sleep hygiene optimization - consistent schedule, sleep environment modification
• Screen for and treat sleep apnea if suspected (polysomnography referral) 1
• If pharmacotherapy absolutely necessary, consider melatonin receptor agonists (no anticholinergic effects) 9 or short-term use of newer benzodiazepine receptor agonists with lower side effect profiles 7, though these carry their own risks

Critical caveat: The cumulative anticholinergic burden matters. If the patient takes ANY other medications with anticholinergic properties (antidepressants, urological agents, other antihistamines, muscle relaxants), the combined burden significantly amplifies dementia risk 2, 10. A comprehensive medication review is essential 5, 8, 11.

Common Prescribing Pitfall

Hydroxyzine remains frequently prescribed for sleep despite evidence against its use 12, 13. In Polish long-term care facilities, hydroxyzine was the most commonly used anxiolytic (71.3% of anxiolytic prescriptions) 12, and 62% of homebound elderly with dementia were prescribed anticholinergic drugs 13. This represents inadequate prescribing practice that should be actively corrected 12.

The misconception that "it's just an antihistamine" or "it's over-the-counter safe" ignores the substantial evidence linking chronic anticholinergic exposure to irreversible cognitive decline, even in younger populations 14.